

Chin

## Shine, Kenneth

---

**From:** Chin, Lynda, Md [Lynda\_Chin@dfci.harvard.edu]  
**Sent:** Thursday, August 11, 2011 8:08 AM  
**To:** Shine, Kenneth; DePinho, Ronald  
**Cc:** Masek, Matthew - UT MD Anderson Cancer Center  
**Subject:** RE: Chin

Dear Ken:

This is consistent with my understanding from the start and I have no issue with it.

Thanks

Lynda

---

**From:** Shine, Kenneth [mailto:kshine@utsystem.edu]  
**Sent:** Thursday, August 11, 2011 7:41 AM  
**To:** DePinho, Ronald; Chin, Lynda, Md  
**Cc:** Masek, Matthew - UT MD Anderson Cancer Center  
**Subject:** FW: Chin

Dear Ron and Lynda. These are guidelines which have provided to Colleagues at MDACC, including Ray Dubois, Ki Hong, Leon Leach and Dan Fontaine. They are designed to provide clarity and to answer any outside questions about our arrangements. The statement has been reviewed by General Counsel and has been found appropriate. Let me know if you have any questions. There is great excitement on the campus about your future contributions and we look forward to your arrival with great excitement. Ken

Dear Colleagues: As you know we have completed the recruitment of Dr. Ronald DePinho as the President of the M. D. Anderson Cancer Center (MDACC) effective September 1, 2011. President Designate DePinho's wife, Dr. Lynda Chin, is a very accomplished physician and scientist who will also be joining the faculty at MDACC. She will serve as Chair of a new Department of Genomic Medicine and as Scientific Director of a newly constituted Institute for Applied Cancer Science. In view of her relationship to the President designate I have conducted, in consultation with faculty and staff at MDACC, the recruitment of Dr. Chin, including her salary, the resources required for her personal laboratory and for the Department of Genomic Medicine. I have also approved the organization, business plan and budget for the Institute of Applied Cancer Science. As Chair of the Department of Genomic Medicine Dr. Chin will report to Dr. Waun Ki Hong, Head of the Division of Cancer Medicine. As Scientific Director of the Institute, Dr. Chin with the Administrative Director of the Institute, Dr. Giulio Draetta, will report to Provost Raymond Dubois. Drs. Hong and Dubois will have direct responsibility for supervising Dr. Chin, evaluating her performance, identifying resources needed for her programs, assisting in recruitment efforts by her, and otherwise functioning in the usual manner required by their responsibilities. However, so long as Dr. DePinho is President he will not participate in any of these functions so far as his wife is concerned. At any time when a Presidential action is required in regard to any of these activities, or any other activities of Dr. Chin's employment, the Executive Vice Chancellor (EVC) for Health Affairs will be consulted and the EVC for Health Affairs approval will be required in place of any Presidential action. This includes setting Dr. Chin's salary, promotion, or any other substantial change in her status. It also includes any additional provision of institutional resources which would ordinarily require Presidential approval. Any committee report concerning Dr. Chin, such as those of the Conflict of Interest Committee, which would ordinarily be made to the President of MDACC will be sent to the EVC for Health Affairs. Dr. Chin's annual performance review will be provided to the EVC for Health Affairs. These arrangements are consistent with Regents' rule 30106 regarding Nepotism. We are very excited for the future impacts of Dr. Chin and President DePinho upon MDACC and upon Cancer discoveries and treatment. Let me know if you have any questions about these arrangements.